These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 26745764)
1. Annual patient and caregiver burden of oncology clinic visits for granulocyte-colony stimulating factor therapy in the US. Stephens JM; Li X; Reiner M; Tzivelekis S J Med Econ; 2016; 19(5):537-47. PubMed ID: 26745764 [TBL] [Abstract][Full Text] [Related]
2. Travel burden associated with granulocyte colony-stimulating factor administration in a Medicare aged population: a geospatial analysis. Stephens JM; Bensink M; Bowers C; Hollenbeak CS Curr Med Res Opin; 2018 Aug; 34(8):1351-1360. PubMed ID: 28722536 [TBL] [Abstract][Full Text] [Related]
3. Risks and consequences of travel burden on prophylactic granulocyte colony-stimulating factor administration and incidence of febrile neutropenia in an aged Medicare population. Stephens JM; Bensink M; Bowers C; Hollenbeak CS Curr Med Res Opin; 2019 Feb; 35(2):229-240. PubMed ID: 29661043 [TBL] [Abstract][Full Text] [Related]
4. Discrete choice experiment to estimate breast cancer patients' preferences and willingness to pay for prophylactic granulocyte colony-stimulating factors. Johnson P; Bancroft T; Barron R; Legg J; Li X; Watson H; Naeim A; Watkins A; Marshall DA Value Health; 2014 Jun; 17(4):380-9. PubMed ID: 24968998 [TBL] [Abstract][Full Text] [Related]
5. Pharmacoeconomics of granulocyte colony-stimulating factor: a critical review. Barnes G; Pathak A; Schwartzberg L Adv Ther; 2014 Jul; 31(7):683-95. PubMed ID: 24989316 [TBL] [Abstract][Full Text] [Related]
6. A retrospective study of patients' out-of-pocket costs for granulocyte colony-stimulating factors. Tomic K; Long S; Li X; Fu AC; Yu TC; Barron R J Oncol Pharm Pract; 2013 Dec; 19(4):328-37. PubMed ID: 23353712 [TBL] [Abstract][Full Text] [Related]
7. Economic evaluation of intensive chemotherapy with prophylactic granulocyte colony-stimulating factor for patients with high-risk early breast cancer in Japan. Ishiguro H; Kondo M; Hoshi SL; Takada M; Nakamura S; Teramukai S; Yanagihara K; Toi M Clin Ther; 2010 Feb; 32(2):311-26. PubMed ID: 20206789 [TBL] [Abstract][Full Text] [Related]
8. Cost effectiveness of primary pegfilgrastim prophylaxis in patients with breast cancer at risk of febrile neutropenia. Aarts MJ; Grutters JP; Peters FP; Mandigers CM; Dercksen MW; Stouthard JM; Nortier HJ; van Laarhoven HW; van Warmerdam LJ; van de Wouw AJ; Jacobs EM; Mattijssen V; van der Rijt CC; Smilde TJ; van der Velden AW; Temizkan M; Batman E; Muller EW; van Gastel SM; Joore MA; Borm GF; Tjan-Heijnen VC J Clin Oncol; 2013 Dec; 31(34):4283-9. PubMed ID: 24166522 [TBL] [Abstract][Full Text] [Related]
9. Therapeutic use of granulocyte colony-stimulating factors for established febrile neutropenia: effect on costs from a hospital perspective. Cosler LE; Eldar-Lissai A; Culakova E; Kuderer NM; Dale D; Crawford J; Lyman GH Pharmacoeconomics; 2007; 25(4):343-51. PubMed ID: 17402806 [TBL] [Abstract][Full Text] [Related]
10. Economic analysis of prophylactic pegfilgrastim in adult cancer patients receiving chemotherapy. Eldar-Lissai A; Cosler LE; Culakova E; Lyman GH Value Health; 2008; 11(2):172-9. PubMed ID: 18380630 [TBL] [Abstract][Full Text] [Related]
11. Economic implications of using pegfilgrastim rather than conventional G-CSF to prevent neutropenia during small-cell lung cancer chemotherapy. Tan Sean P; Chouaid C; Hettler D; Baud M; Hejblum G; Tilleul P Curr Med Res Opin; 2009 Jun; 25(6):1455-60. PubMed ID: 19419340 [TBL] [Abstract][Full Text] [Related]
12. Use of granulocyte colony-stimulating factor (G-CSF) in patients receiving myelosuppressive chemotherapy for the treatment of cancer. Provincial Systemic Treatment Disease Site Group. Rusthoven J; Bramwell V; Stephenson B Cancer Prev Control; 1998 Aug; 2(4):179-90. PubMed ID: 10093631 [TBL] [Abstract][Full Text] [Related]
13. Effect of outpatient treatment of febrile neutropenia on the risk threshold for the use of CSF in patients with cancer treated with chemotherapy. Cosler LE; Sivasubramaniam V; Agboola O; Crawford J; Dale D; Lyman GH Value Health; 2005; 8(1):47-52. PubMed ID: 15841893 [TBL] [Abstract][Full Text] [Related]
15. The long-term social value of granulocyte colony-stimulating factors. Sexton Ward A; Kabiri M; Yucel A; Silverstein AR; van Eijndhoven E; Bowers C; Bensink M; Goldman D Am J Manag Care; 2019 Oct; 25(10):486-493. PubMed ID: 31622064 [TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of granulocyte colony-stimulating factor prophylaxis for febrile neutropenia in breast cancer in the United Kingdom. Whyte S; Cooper KL; Stevenson MD; Madan J; Akehurst R Value Health; 2011 Jun; 14(4):465-74. PubMed ID: 21669371 [TBL] [Abstract][Full Text] [Related]
17. Impact of cancer supportive care pathways compliance on emergency department visits and hospitalizations. Kreys ED; Kim TY; Delgado A; Koeller JM J Oncol Pract; 2014 May; 10(3):168-73. PubMed ID: 24839275 [TBL] [Abstract][Full Text] [Related]
18. Modeling the cost-effectiveness of granulocyte colony-stimulating factor use in early-stage breast cancer. Silber JH; Fridman M; Shpilsky A; Even-Shoshan O; Smink DS; Jayaraman J; Fox KR; Pauly MV J Clin Oncol; 1998 Jul; 16(7):2435-44. PubMed ID: 9667261 [TBL] [Abstract][Full Text] [Related]
19. A novel approach to maintain planned dose chemotherapy on time: a decision-making tool to improve patient care. Lyman GH Eur J Cancer; 2000 Apr; 36 Suppl 1():S15-21. PubMed ID: 10785605 [TBL] [Abstract][Full Text] [Related]
20. Economic evaluations of granulocyte colony-stimulating factor: in the prevention and treatment of chemotherapy-induced neutropenia. Esser M; Brunner H Pharmacoeconomics; 2003; 21(18):1295-313. PubMed ID: 14750898 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]